NextCure (NASDAQ:NXTC) Posts Quarterly Earnings Results, Misses Estimates By $0.85 EPS

NextCure (NASDAQ:NXTC) released its quarterly earnings results on Thursday. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($0.85), FiscalAI reports.

NextCure Trading Up 4.5%

Shares of NextCure stock traded up $0.25 on Friday, hitting $5.84. 290,316 shares of the company traded hands, compared to its average volume of 6,419,686. NextCure has a 12-month low of $1.55 and a 12-month high of $15.74. The company has a market cap of $21.08 million, a P/E ratio of -0.67 and a beta of 1.27. The firm’s 50-day simple moving average is $3.35 and its 200 day simple moving average is $8.41.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NXTC shares. Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NextCure in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Insider Transactions at NextCure

In other news, major shareholder Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock in a transaction that occurred on Thursday, July 30th. The shares were acquired at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the completion of the purchase, the insider directly owned 686,116 shares in the company, valued at $3,382,551.88. The trade was a 74.47% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have acquired 346,761 shares of company stock valued at $1,710,807 in the last ninety days. 11.90% of the stock is currently owned by insiders.

Institutional Trading of NextCure

Hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC purchased a new stake in NextCure in the fourth quarter worth approximately $3,382,000. Squadron Capital Management LLC purchased a new position in shares of NextCure during the fourth quarter worth approximately $3,363,000. Millennium Management LLC purchased a new position in shares of NextCure during the fourth quarter worth approximately $185,000. Boothbay Fund Management LLC bought a new stake in shares of NextCure in the 4th quarter worth approximately $988,000. Finally, Marshall Wace LLP bought a new stake in shares of NextCure in the 4th quarter worth approximately $160,000. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.